OTCMKTS:CVSI CV Sciences (CVSI) Stock Price, News & Analysis $0.03 +0.00 (+1.79%) As of 04/25/2025 03:44 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesSEC FilingsShort InterestBuy This Stock About CV Sciences Stock (OTCMKTS:CVSI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CV Sciences alerts:Sign Up Key Stats Today's Range$0.03▼$0.0350-Day Range$0.03▼$0.0452-Week Range$0.03▼$0.10Volume96,081 shsAverage Volume205,741 shsMarket Capitalization$5.27 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewCV Sciences, Inc. develops, manufactures, markets, and sells herbal supplements and hemp-based cannabidiol (CBD) in North America. It operates in two segments, Consumer Products and Specialty Pharmaceutical. The company offers its products under the PlusCBD, ProCBD, HappyLane, CVAcute, CVDefense, and PlusCBD Pet brands in the health care market sector, including nutraceutical, beauty care, specialty foods, and pet products through its websites, elect distributors, brick and mortar retailers, and select e-tailers. It is also developing cannabinoids intended to treat medical indications, including CVSI-007 that combines CBD and nicotine for the treatment of smokeless tobacco use and addiction. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.Read More… CV Sciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks2nd Percentile Overall ScoreCVSI MarketRank™: CV Sciences scored higher than 2% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for CV Sciences. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of CV Sciences is -2.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CV Sciences is -2.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCV Sciences has a P/B Ratio of 1.43. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.02% of the float of CV Sciences has been sold short.Short Interest Ratio / Days to CoverCV Sciences has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CV Sciences has recently increased by 534.38%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCV Sciences does not currently pay a dividend.Dividend GrowthCV Sciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.02% of the float of CV Sciences has been sold short.Short Interest Ratio / Days to CoverCV Sciences has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CV Sciences has recently increased by 534.38%, indicating that investor sentiment is decreasing significantly. News and Social Media0.6 / 5News SentimentN/A News SentimentCV Sciences has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.86 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for CV Sciences this week, compared to 0 articles on an average week. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, CV Sciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.30% of the stock of CV Sciences is held by insiders.Read more about CV Sciences' insider trading history. Receive CVSI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CV Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address CVSI Stock News HeadlinesCV Sciences, Inc. (PNK:CVSI) Q4 2024 Earnings Call TranscriptMarch 28, 2025 | insidermonkey.comQ4 2024 CV Sciences Inc Earnings CallMarch 28, 2025 | finance.yahoo.comFrom Social Security to Social Prosperity?In less than a decade, Social Security could be out of money. But a surprising plan from Trump’s inner circle may not just save the system — it could unlock a major opportunity for savvy investors. Financial insider Jim Rickards calls it “Social Prosperity,” and says those who act now could see the biggest gains.April 28, 2025 | Paradigm Press (Ad)CV Sciences targets profitability with new product lines and M&A strategy in 2025March 27, 2025 | msn.comCV Sciences, Inc. (CVSI) Q4 2024 Earnings Call TranscriptMarch 27, 2025 | seekingalpha.comCV Sciences, Inc.: CV Sciences Unveils Lunar Fox Food Co., an All-New Line of Plant-Based FoodsMarch 27, 2025 | finanznachrichten.deCV Sciences, Inc. To Announce Year End and Fourth Quarter 2024 Results On March 27, 2025March 20, 2025 | gurufocus.comCV Sciences Disputes Stock Purchase Agreement TerminationFebruary 11, 2025 | tipranks.comSee More Headlines CVSI Stock Analysis - Frequently Asked Questions How have CVSI shares performed this year? CV Sciences' stock was trading at $0.0338 at the start of the year. Since then, CVSI shares have decreased by 15.7% and is now trading at $0.0285. View the best growth stocks for 2025 here. How were CV Sciences' earnings last quarter? CV Sciences, Inc. (OTCMKTS:CVSI) issued its quarterly earnings results on Thursday, August, 12th. The company reported ($0.03) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.03). The business had revenue of $5.13 million for the quarter, compared to analysts' expectations of $5.12 million. CV Sciences had a negative trailing twelve-month return on equity of 101.85% and a negative net margin of 16.24%. How do I buy shares of CV Sciences? Shares of CVSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CV Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that CV Sciences investors own include Canopy Growth (CGC), Aurora Cannabis (ACB), Charlotte's Web (CWBHF), Cronos Group (CRON), KushCo (KSHB), NVIDIA (NVDA) and Organigram (OGI). Company Calendar Last Earnings8/12/2021Today4/27/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:CVSI Previous SymbolNASDAQ:CVSI CIK1510964 Webwww.cvsciences.com Phone(866) 290-2157Fax619-876-4321Employees70Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$3.10 million Net Margins-16.24% Pretax Margin-16.26% Return on Equity-101.85% Return on Assets-29.04% Debt Debt-to-Equity RatioN/A Current Ratio1.10 Quick Ratio0.28 Sales & Book Value Annual Sales$16 million Price / Sales0.33 Cash Flow$0.02 per share Price / Cash Flow1.75 Book Value$0.02 per share Price / Book1.43Miscellaneous Outstanding Shares184,794,000Free Float182,392,000Market Cap$5.27 million OptionableNot Optionable Beta0.53 Social Links 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free Report This page (OTCMKTS:CVSI) was last updated on 4/28/2025 by MarketBeat.com Staff From Our Partners$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredThe Last Time This Happened, Americans Lost BillionsWall Street leaders just held a secret meeting in Las Vegas. What they discussed mirrors 2006 — and the warnin...Banyan Hill Publishing | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CV Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CV Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.